miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma

Biomolecules

Pei-Jung Chung¹  Nianhan Ma¹  Mai-Huong Thi Nguyen¹  An-Lun Li¹  Kun-Lin Wu¹  Yueh-Hsia Luo²  Jen-Chieh Tsai³ 

[1] Department of Biomedical Sciences and Engineering, National Central University, Taoyuan 320317, Taiwan;Department of Life Sciences, National Central University, Taoyuan 320317, Taiwan;Institute of Biotechnology, National Tsing Hua University, Hsinchu 300044, Taiwan;

关键词: immunotherapy;    resistance;    miRNA;    biomarker;   

DOI  :  10.3390/biom11111648

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors are a promising therapy for the treatment of cancers, including melanoma, that improved benefit clinical outcomes. However, a subset of melanoma patients do not respond or acquire resistance to immunotherapy, which limits their clinical applicability. Recent studies have explored the reasons related to the resistance of melanoma to immune checkpoint inhibitors. Of note, miRNAs are the regulators of not only cancer progression but also of the response between cancer cells and immune cells. Investigation of miRNA functions within the tumor microenvironment have suggested that miRNAs could be considered as key partners in immunotherapy. Here, we reviewed the known mechanism by which melanoma induces resistance to immunotherapy and the role of miRNAs in immune responses and the microenvironment.

【 授权许可】

Unknown